Navigation Links
Thomson Reuters and ChemAxon Partner to Help Speed Drug Discovery for Life Science Researchers
Date:1/4/2011

LONDON and BUDAPEST, Hungary, Jan. 4, 2011 /PRNewswire/ -- The IP Solutions business of Thomson Reuters®, the leader in intellectual property research and analysis solutions, and ChemAxon, the leader in cheminformatics software for the life sciences industry, today announced a strategic partnership whereby Thomson Reuters is providing its chemical IP Data Feeds – Markush Structures and patent data to users of ChemAxon's JChem chemical software platform. This search and analysis solution will speed drug discovery and allow life science researchers to easily integrate critical content into their existing systems and workflow.

(Photo:  http://photos.prnewswire.com/prnh/20110104/NY24167)

The Markush structures from Thomson Reuters are part of the company's Derwent World Patents Index® (DWPI(SM)) database, the world's most trusted and authoritative source of global patent information. The Markush database contains essential data on the relationship or "families" of 550,000 patents, making it the world's leading source for life sciences patentability research, competitive intelligence and IP screening.  ChemAxon's JChem software allows life science professionals to structure and visualize chemical compounds for property prediction, virtual synthesis, screening and drug design. Through this partnership R&D end users can now research and analyze Markush structures using ChemAxon's JChem chemical software platform, a means they had no access to before.  The ability to quickly retrieve this information will now allow R&D end users to save time and capitalize on R&D investment.

"The ability to search and visualize complex chemical patents is critical to the work of life science R&D professionals. To date, however, this has been a challenge as there wasn't a tool that enabled R&D end users to do this type of work themselves," said Cindy Poulos, vice president of product management, Thomson Reuters. "Through this partnership, Thomson Reuters and ChemAxon are making a comprehensive worldwide database of chemical compounds widely accessible in a user-friendly, flexible format to end users."

"The Markush structures database has become a vital backbone of pharmaceutical research in the digital age," said Alex Drijver, CEO of ChemAxon.  "By delivering this data directly to the end user in an intuitive, flexible format, our clients have access to the functionality and data necessary to stay competitive in today's fast-paced, complex marketplace."

The Thomson Reuters IP Data Feed - Markush Structures database is indexed from 550,000 patent families, plus 1.7 million related, exemplified, specific compounds.  It includes patents for pharmaceuticals, agrochemicals and general chemistry spanning 26 patent-issuing authorities.  Markush data is integrated with high-quality patent summary data from DWPI, enabling access to enhanced patent abstracts, family and assignee details, and relevant bibliographic data.  For more information, contact Steve Hajkowski, product manager, Thomson Reuters, at steve.hajkowski@thomsonreuters.com

About ChemAxon Ltd

ChemAxon is a leader in providing cheminformatics software development platforms and applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Rush-Copley Medical Center Selects Pharmacy Xpert from Thomson Reuters to Improve Medication Management
2. US Dominance in Scientific Research Significantly Challenged by Increased Competition from Europe and Asia, According to Thomson Reuters Study
3. Generic Drug Sector Gets Better Information on API Manufacturing Costs from Thomson Reuters and Rondaxe Enterprises
4. GenomeQuest & Thomson Reuters Host IP Seminar
5. Thomson Reuters Names the Worlds Hottest Researchers
6. Thomson Reuters Launches Academic Reputation Survey as Part of Global Institutional Profiles Project
7. Australia Substantially Increases Research Collaboration with China, According to Thomson Reuters Study
8. Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials
9. Chinas Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals
10. Thomson Reuters Explores the Opportunities and Challenges of Entering the Japanese Generic Drug Market
11. Thomson Reuters Predicts Nobel Laureates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... Business Report" report to their offering. ... This report analyzes the Global market ... estimates and forecasts are provided for the period 2014 through 2022. ... The report profiles 25 companies including many key ...
(Date:3/24/2017)... 2017   Sienna Biopharmaceuticals, Inc. , a privately ... that Richard Peterson will join the company ... Peterson, who brings more than two decades of global ... is retiring at the end of April but will ... joins Sienna from Novan, Inc., where he served as ...
(Date:3/23/2017)... San Diego, Calif. (PRWEB) , ... March 23, 2017 , ... Lajollacooks4u is proud to ... in 2008, it has hosted corporate cooking challenges for companies around the world, such as ... , Part of the reason for its increasing popularity is due to its new ...
(Date:3/23/2017)... , March 23, 2017  SeraCare Life ... global in vitro diagnostics manufacturers and clinical ... industry,s first multiplexed Inherited Cancer reference ... by next-generation sequencing (NGS). The Seraseq™ Inherited ... with input from industry experts to validate ...
Breaking Biology Technology:
(Date:2/28/2017)... Februar 2017  EyeLock LLC, ein marktführendes Unternehmen im ... biometrische Lösung zur Iris-Erkennung auf der neuesten ... auf dem Mobile World Congress 2017 (27. ... Halle 3, Stand 3E10, vorstellen. ... Haven™ – eine Kombination aus Hardware, Software ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/21/2017)... 2017 Der weltweite Biobanking-Sektor wird ... einem Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen ... gilt, um diese Prognose zu realisieren. ... Zu den ... finanziellen Mittel für die Biobank, die Implementierung Zeit sparender ...
Breaking Biology News(10 mins):